ClinicalTrials.gg
RecruitingNCT05424354Updated Nov 19, 2025

Acute Partial Thickness Burn Study Comparing Transforming Powder Dressing to Standard of Care Dressing

A Phase 4 interventional study of Altrazeal (R) Transforming Powder Dressing and Standard of Care burn dressing in Wounds and Injuries, sponsored by ULURU Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-19.

Primary conditionBurnsRegistry: Wounds and InjuriesReclassifiedWhy we changed it
Registry
Wounds and Injuries — the first condition term the registry derived for this study.
ClinicalTrials.gg
Burns
Why
  1. The study's title name Burns, a narrower term within Wounds and Injuries.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ULURU Inc. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 336 studies in Burns with a site in United States — 40 open to participants now, 51 under way, 5 of them phase 3. Burns · United States.

Planned enrollment
59th of 272
60 · median 26
Started
2022
with 12 others
Phase 4
25 of 336
6 open now
Primary completion
2026-06
later than 13 of 50 live
Registered
280th of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 59th largest by planned enrollment of the 272 interventional ones that give a count, is one of 13 that started in 2022, is one of 25 in phase 4, reaches primary completion later than 13 of the 50 other live ones, and was the 280th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

This study is being performed to assess the effectiveness of Altrazeal(R) Transforming Powder Dressing (TPD) in patients with partial thickness burns compared to the current standard of care (SOC) dressing. Adult men and women 18-65 years old who are hospitalized with an acute (meaning the burn injury occurred less than 72 hours prior to enrollment in the study) partial thickness burn wound, less than 20 percent of total body surface area may be considered. Subjects will be randomized in a 1:1 ratio to either SOC or TPD. Subjects will be followed for up to 28 days after enrollment.

Read the detailed description

This post-marketing study is being performed to assess the effectiveness of Altrazeal(R) Transforming Powder Dressing (TPD) in patients with partial thickness burns compared to the current standard of care (SOC) dressing for burn wounds. Adult men and women 18-65 years old who are hospitalized with an acute (meaning the burn injury occurred less than 36 hours prior to enrollment in the study) partial thickness burn wound, comprising less than 20 percent of total body surface area may be considered. Subjects will be randomized in a 1:1 ratio to either SOC or TPD. Subjects will be followed during hospitalization and then upon discharge from the hospital for up to 28 days after enrollment into the study. At each of the 8 study visits, the burn wound will be evaluated, photographed and measured. The wound will be cleaned and debrided, if needed, per usual standard burn care. A wound dressing will be applied using TPD or a typical SOC dressing. Wound healing and wound pain will be monitored at each visit, and the results of the two groups (TPD and SOC) will be compared to each other. A survey evaluating the satisfaction with the dressing received will be given at the end of the study, or when the wound heals, whichever comes first.

03

Conditions studied

  • Wounds and Injuries

Browse trials for

Keywords

  • burn
04

In context

Burns Reclassified

906 studies on the registry are indexed under Burns; 165 are open to participants now.

This study's planned enrollment of 60 is above the median of 40 across 664 interventional studies indexed under Burns.

Browse Burns studies →

Lead sponsor

ULURU Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Compared within Burns, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Wounds and Injuries. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients who are receiving burn care; patients may be discharged when clinically stable and continue with outpatient treatment.
  • Men and women (women cannot be pregnant or breast feeding) ages 18-65 years old
  • Wounds must be partial thickness, involving up to 20% of the total body surface area.
  • Burn injury should be less than 72 hours old
  • Willing and able to comply with protocol mandated scheduled study visits/clinical evaluations.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Known allergy to TPD or its components

    • Women who are pregnant, breast feeding, or plan to get pregnant during the study period.
  • Infected wounds
  • Presence of any full thickness (third degree) burns
  • Electrical burns
  • Heavily draining burns due to underlying chronic lymphedema or other conditions
  • Concurrent clinical condition within the judgement of the clinician, pose a health risk to the patient, delay wound healing, or otherwise influence the outcome of the study.
  • History of poor wound healing and/or skin/immune system condition

    • Deemed by clinician not to be suitable
  • Unwilling or not able to provide consent or comply with protocol or required visits
  • Developmental disability/significant psychological disorder which can impair the subjects ability to provide , or participate in the study protocol
  • Active alcohol or substance abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Transforming Powder Dressing

    Half of the subjects will be randomized to Transforming Powder Dressing (TPD) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. TPD will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).

    Device: Altrazeal (R) Transforming Powder Dressing

  • Active comparator
    Standard of Care Dressing

    Half of the subjects will be randomized to Standard of Care (SOC) to treat the burn wound(s). Subjects will be evaluated on Treatment Day 0, 3, 7, 10, 14, 21, and 28 (or sooner if the wound heals prior to end of study visit on Day 28). On each study visit, wound care will be performed. The standard of care burn dressing will be applied directly on the burn wound, followed by another dressing (often called a secondary dressing).

    Other: Standard of Care burn dressing

Interventions

  • DeviceAltrazeal (R) Transforming Powder Dressing

    After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with Altrazeal TPD.

  • OtherStandard of Care burn dressing

    After informed consent and the subject is determined to meet all selection criteria, randomization will occur in a 1:1 ratio, to determine the treatment arm of the study. Half of those randomized will receive burn care with the institution's standard of care burn dressing.

07

What researchers measure

Primary outcomes

  1. Pain from the Burn Wound

    Subjects will complete a visual analogue scale (VAS) to rate their pain prior to, during and after dressing changes. The scale ranges from 0 to 10, with 0 indicating no pain and 10 indicating the worst pain possible.

    Time frame: 28 days (or sooner if the wound heals prior to 28 days)

Secondary outcomes

  1. Wound healing

    Wounds will measured at each study visit to determine surface area healing.

    Time frame: 28 days (or sooner if the wound heals prior to 28 days)

  2. Safety of the Interventions (TPD and SOC)

    Complications such as infection, and other adverse events that develop will be documented, evaluated for severity, and compared between intervention groups.

    Time frame: 28 days (or sooner if the wound heals prior to 28 days)

  3. Subject satisfaction

    Subjects will be asked to complete a subject satisfaction survey, which consists of 8 multiple choice questions regarding their wound dressing.

    Time frame: End of Study

08

Study locations

6 of 6 sites recruiting
  • University of California-Irvine
    Orange, California 92868, United States
    Recruiting
    • Lizette Spears · Contactlspiers@hs.uci.edu · 714-456-5840
    • Taina Aruju · Contacttaraujo@hs.uci.edu · 714-456-5840
    • Victor Joe, MD · Principal investigator
    • Theresa Chin, MD · Sub investigator
    • Kimberly Burton, PA · Sub investigator
  • MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Jackson Memorial Hospital UM/JMH Burn Center
    Miami, Florida 33136, United States
    Recruiting
    • Lisa Otero, BA · Contactlao77@med.miami.edu · 305-585-1348
    • Carl I Schulman, MD · Principal investigator
    • Joyce I Kaufman, MD · Sub investigator
    • Louis R Pizano, MD · Sub investigator
    • Shevonne S Satahoo, MD · Sub investigator
  • University of Louisville Health
    Louisville, Kentucky 40202, United States
    Recruiting
  • Westchester Medical Center
    Valhalla, New York 10595, United States
    Recruiting
  • University of Texas SW (Parkland)
    Dallas, Texas 75235, United States
    Recruiting
    • Scarlett Dwyer · ContactScarlett.Dwyer@utsouthwestern.edu · 214 645-0445
    • Caroline Park, MD · Principal investigator
    • Chiaka Akarichi, MD · Sub investigator
    • Rebecca Coffey, PhD · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Jun 2026, 49 months after the start.

Of 21 phase 4 interventional studies under Burns, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 43. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2022
First posted
Jun 21, 2022
StartActual
May 26, 2022
Primary completionEst.
Jun 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05424354
Lead sponsor
ULURU Inc.
Collaborators
Navy Advanced Medical Development (NAMD) Command
Responsible party
Sponsor
First posted
Jun 21, 2022
Start date
May 26, 2022
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Vai Shah
Contact
vshah@uluruinc.com
2149055145
Susan St John, MSN
Contact
sstjohn@uluru.com
4123035379
Jonathan Saxe, MD
principal investigator · ULURU Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion